Bidirectional autoregulatory mechanism of metastasis-associated protein 1-alternative reading frame pathway in oncogenesis by Li, D.-Q. et al.
Bidirectional autoregulatory mechanism of
metastasis-associated protein 1-alternative
reading frame pathway in oncogenesis
Da-Qiang Lia, Suresh B. Pakalaa, Sirigiri Divijendra Natha Reddya, Kazufumi Ohshiroa, Jun-Xiang Zhanga, Lei Wangb,
Yanping Zhangc, Ignacio Moreno de Alboránd, M. Radhakrishna Pillaie, Jeyanthy Eswarana,f, and Rakesh Kumara,e,f,1
aDepartment of Biochemistry and Molecular Biology and fMcCormick Genomic and Proteomic Center, The George Washington University Medical Center,
Washington, DC 20037; bDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030; cRadiation Oncology and Lineberger
Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514; dDepartment of Immunology and Oncology, National Center
for Biotechnology, 28049 Madrid, Spain; and eRajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India
Edited* by George R. Stark, Lerner Research Institute NE2, Cleveland, OH, and approved April 8, 2011 (received for review December 8, 2010)
Althoughmetastasis-associatedprotein1 (MTA1), a componentof the
nucleosome remodelingandhistonedeacetylation complex, iswidely
up-regulated in human cancers and correlateswith tumormetastasis,
its regulatory mechanism and related signaling pathways remain
unknown. Here, we report a previously unrecognized bidirectional
autoregulatory loop between MTA1 and tumor suppressor alter-
native reading frame (ARF). MTA1 transactivates ARF transcription
by recruiting the transcription factor c-Jun onto the ARF promoter in
a p53-independent manner. ARF, in turn, negatively regulates MTA1
expression independently ofp53 and c-Myc. In this context, ARF inter-
acts with transcription factor specificity protein 1 (SP1) and promotes
its proteasomaldegradationbyenhancing its interactionwithprotea-
some subunit regulatory particle ATPase 6, thereby abrogating the
ability of SP1 to stimulate MTA1 transcription. ARF also physically
associates with MTA1 and affects its protein stability. Thus, MTA1-
mediated activation of ARF and ARF-mediated functional inhibition
of MTA1 represent a p53-independent bidirectional autoregulatory
mechanism in which these two opposites act in concert to regulate
cell homeostasis and oncogenesis, depending on the cellular context
and the environment.
Chromatin-remodeling factors play a crucial role in the regula-tion of gene expression during cellular differentiation and
development. One newly added group of ubiquitously expressed
chromatin modifiers is the metastasis-associated protein (MTA)
family, members of which play an integral role in nucleosome
remodeling and histone deacetylation complexes thatmodifyDNA
accessibility to cofactors (1). MTA1, the founding member of the
MTA family, functions not only as a transcriptional repressor
of estrogen receptor-α (2) and breast cancer type 1 susceptibility
protein (3) but also as a transcriptional activator of some genes
such as breast carcinoma-amplified sequence 3 (BCAS3) (4) and
paired box 5 (5), largely because of its ability to interact with RNA
polymerase II (Pol II). MTA1 also is an essential downstream
effector of c-Myc oncoprotein (6). Although MTA1 is widely up-
regulated in human cancers and plays an important role in tu-
morigenesis and tumor metastasis (7), its regulatory mechanism
and related signaling transduction pathways are not clear.
Through their ability to activate a number of progrowth and
prosurvival pathways, oncogenes potently promote tumor initia-
tion and progression (8). However, evolution has installed a variety
of innate tumor-suppressive mechanisms in the proliferative pro-
gram ofmammalian cells that trigger apoptosis or senescence once
proliferation becomes aberrant (9). One of the main mediators of
the antioncogenic programs is the alternative reading frame (ARF)
tumor suppressor (known as “p14ARF” in humans and “p19ARF”
in mice; referred to as “ARF” hereafter), one of two products of
the inhibitor of cyclin-dependent kinase 4a (INK4a)/ARF locus
on chromosome 9p21 (10). The principal function of ARF is to
counteract hyperproliferative signals emanating from constitu-
tively activated oncogenes through modulating the activity of p53
transcription factor by antagonizing the p53-specific ubiquitin li-
gase mouse double minute 2 (Mdm2) (11). Recently, ARF has
been reported to associate with proteins other than Mdm2 and to
have p53-independent tumor-suppressive activities (11). For ex-
ample, mice null for ARF, p53, and Mdm2 experienced tumor de-
velopment at a higher frequency than did mice lacking both p53 and
Mdm2 or p53 alone (12). These studies indicate that the tumor-
suppressive functions of ARF are not elicited entirely through the
Mdm2/p53 pathway and that additional cell factors must be targeted
by ARF. In support of this notion, several ARF target proteins have
been reported over the years (11), but these p53-independent
activities of ARF remain poorly understood. Here, we report
a p53-independent autoregulatory feedback loop betweenMTA1
and ARF in oncogenesis.
Results and Discussion
MTA1 Is a Transcriptional Coactivator of the ARF Gene. The ability of
oncogenes to engage tumor-suppressor pathways represents a key
regulatory mechanism that can limit the outgrowth of incipient
tumor cells (8). To explore whetherMTA1 interjects into theARF-
mediated tumor-suppressive pathway, we first evaluated the effect
of endogenous MTA1 on the expression levels of ARF protein
using mouse embryonic fibroblasts (MEFs) derived from wild-type
andMTA1-knockout (MTA1−/−)mice (13). Surprisingly, knockout
ofMTA1 resulted in a dramatic decrease in the expression levels of
p19ARF protein in MTA1−/− MEFs relative to wild-type controls
(Fig. 1A). Consistently, a significant decrease in the expression of
MTA1 protein was accompanied by a drastic down-regulation of
p19ARF protein in MTA1 siRNA-transfected cells compared
with control siRNA-treated cells (Fig. 1B). By contrast, intro-
duction of MTA1 in HC11 murine mammary epithelial cells led
to a significant increase in p19ARF protein expression (Fig. 1C).
Because HC11 cells carry two mutant p53 alleles and lack a func-
tional p53 gene (14), we speculated that the regulation of ARF by
MTA1 is p53 independent. To test this notion, we next depleted the
endogenous MTA1 in p53−/−/Mdm2−/− MEFs (15) using specific
siRNAs targeting MTA1 and observed a similar effect of MTA1
on p19ARF protein expression (Fig. 1D), suggesting that MTA1
regulates p19ARF expression in a p53-independent manner.
To address the mechanism of MTA1 regulation of p19ARF,
we next tested whether MTA1 affects p19ARF transcription.
Results showed that the mRNA levels of the p19ARF gene de-
creased significantly in MTA1−/− MEFs compared with wild-type
controls (Fig. 1E Left). In contrast, p19ARF mRNA levels were
elevated significantly in HC11 stable clone cells overexpressing
MTA1 (HC11/MTA1) compared with controls expressing empty
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vector (HC11/pcDNA) (Fig. 1E Right). These results suggest that
MTA1 regulates p19ARF expression, at least in part, at the tran-
scriptional level. In support of this notion, we found significantly
reduced p19ARF promoter activity in MTA1−/− MEFs relative to
wild-type controls (Fig. 1F Left). In contrast, p19ARF promoter
activity was elevated in HC11/MTA1 cells compared with HC11/
pcDNA controls (Fig. 1F Right). Consistently, a dose-dependent
increase in p19ARF promoter activity also was observed in p53−/−/
Mdm2−/− cells in response to MTA1 expression (Fig. 1G). Collec-
tively, these results clearly show that MTA1 functions as a coac-
tivator of p19ARF transcription in a p53-independent manner.
To investigate whether the effect of MTA1 transactivation of
ARF is limited to the murine system, we next validated these
findings using human H1299 lung cancer cells, a p53-null cell line
because of gene truncation (16) that has been used widely for
investigating p53-independent cell function and signaling path-
ways. Human p14ARF is about 50% homologous to murine
p19ARF, but mounting evidence suggests that the two proteins
share a set of similar properties. For example, both p19ARF and
p14ARF can interact directly with Mdm2 (11) and suppress cell
adhesion and promote apoptosis (17). It is noteworthy that mouse
MTA1 protein shares 94% homology with human MTA1 protein
(18). We found that knockdown of endogenous MTA1 results in
a significant down-regulation of p14ARF protein and mRNA ex-
pression in H1299 cells (SI Appendix, Fig. S1 A and B). We also
observed a significant reduction in p14ARF promoter activity upon
MTA1 knockdown (SI Appendix, Fig. S1C). These findings suggest
that MTA1 transactivates both mouse and human ARF.
Recruitment of the c-Jun/MTA1/Pol II Coactivator Complex onto the
ARF Promoter. To gain a deeper insight into the regulation of ARF
transcription by MTA1, we next examined the recruitment of
MTA1 onto the ARF promoter using a ChIP-based promoter walk
analysis. We found that MTA1 was recruited onto five regions
(R1–R3, R5, and R6) of the p19ARF promoter in MTA1+/+ but
notMTA1−/−MEFs (Fig. 2A andB and SI Appendix, Fig. S2A). In
support of this finding, a distinct increase in the recruitment of
MTA1 onto these five regions of the ARF promoter was observed
in HC11/MTA1 cells compared with HC11/pcDNA controls (Fig.
2C and SI Appendix, Fig. S2B).
Because MTA1 stimulated ARF transcription, we next tested
the association of MTA1 and Pol II, an indicator of active tran-
scription, on the ARF promoter. A single ChIP with an anti-RNA
Pol II antibody revealed the recruitment of RNA Pol II to three
regions (R1–R3) of p19ARF promoter (SI Appendix, Fig. S3). We
also observed an enhanced recruitment of RNA Pol II onto these
regions of the p19ARF promoter in HC11/MTA1 cells compared
with HC11/pCDNA controls (SI Appendix, Fig. S3). We next
carried out a double ChIP analysis using the HC11/pcDNA and
HC11/MTA1 stable clone cells and found the MTA1/Pol II
complex associates with two specific regions (R2 and R3) of the
p19ARF promoter (Fig. 2 A and D and SI Appendix, Fig. S4).
Because MTA1 is a transcriptional coregulator that interacts
with transcription factors either to activate or to repress the tran-
scription of specific genes (1), we next performed a sequence
analysis of the MTA1-ARF promoter-interacting regions using
the Alibaba 2.1 program (http://www.gene-regulation.com/pub/
programs/alibaba2/index.html?) to examine the nature of the pu-
tative transcription factor binding sites. Interestingly, we found
two putative consensus binding sequences for c-Jun transcription
factor in the MTA1-ARF promoter–interacting regions (SI Ap-
pendix, Fig. S5). We next tested the hypothesis that MTA1 is
a coactivator of the ARF transcription, presumably through the
recruitment of c-Jun transcription factor onto the ARF promoter.
Indeed, the results of a double ChIP analysis demonstrated that
MTA1 and c-Jun proteins were corecruited onto the p19ARF
promoter (R2 and R3) (Fig. 2E and SI Appendix, Fig. S6). These
findings were confirmed further by EMSA analysis. As shown in
Fig. 2F, we found that the noted protein/ARFDNAcomplex could
be supershifted by incubation of the nuclear extracts from the
MTA1+/+ (Fig. 2F Left) but not MTA1−/− (Fig. 2F Right) MEFs
with a specific antibody against MTA1 (lane 3) or c-Jun (lane 4)
but not control IgG (lane 6) at the expense of basal protein/ARF
DNA complexes (lane 2), suggesting that both MTA1 and c-Jun
proteins may interact with the ARF promoter. This notion was
supported further by the finding that coincubation of anti-MTA1
and anti–c-Jun antibodies results in the formation of further
higher-molecular-weight protein/DNA complexes (lane 5).
We next carried out a ChIP analysis to examine whether MTA1
and c-Jun also can recruit onto the human p14ARF promoter in
H1299 cells. We found that MTA1 and c-Jun were recruited to the
same region of the p14ARF promoter (R2) (SI Appendix, Fig. S7
A and B, respectively). Sequence analysis using the Alibaba 2.1
program revealed the conservation of the c-Jun consensus binding
sequences in the human MTA1-p14ARF promoter–interacting
region (SI Appendix, Fig. S7C). These results were validated fur-
ther with a double ChIP wherein we observed thatMTA1 followed
by c-Jun also was recruited to the same region (R2) on the human
p14ARF promoter (SI Appendix, Fig. S7D). These findings, along
with the p14ARF promoter-luciferase studies (SI Appendix, Fig.
S1C), suggest that MTA1 also transactivates human p14ARF ex-
pression by forming a coactivator complex along with c-Jun on
its promoter.
Based on these findings, we next investigated the possibility of
functional cooperation betweenMTA1 and c-Jun in the regulation
of theARF transcription. As expected, coexpression ofMTA1with
c-Jun resulted in a cooperative activation of the ARF promoter
activity in the p53−/−/Mdm2−/− MEFs (SI Appendix, Fig. S8A) and
H1299 cells (SI Appendix, Fig. S8B). We next explored whether
MTA1 could interact directly with c-Jun using GST pull-down
assays. As shown in SI Appendix, Fig. S9A, 35S-labeled, in vitro-
translated c-Jun protein binds to the bromo-adjacent homology
(amino acids 1–164) and C-terminal (amino acids 442–715)
domains of MTA1, whereas MTA1 binds to the DNA-binding
domain (DBD) (amino acids 257–281) of c-Jun protein (SI Ap-
pendix, Fig. S9B). Collectively, these results suggest that MTA1
Fig. 1. MTA1 regulates p19ARF expression. (A) Western blot analysis of the
MTA1+/+ and MTA1−/− MEFs with the indicated antibodies. Vinculin is shown
as a loading control. (B) MTA1+/+ MEFs were transfected with specific siRNAs
targeting MTA1 or control siRNAs and subjected to Western blot analysis
with indicated antibodies. (C) Western blot analysis of HC11 cells stably
expressing T7-MTA1 or empty vector (pcDNA) with the indicated antibodies.
(D) (Left) p53−/−/Mdm2−/− cells were transfected with specific siRNAs tar-
geting MTA1 or control siRNAs and were subjected to Western blot analysis
with the indicated antibodies. The density of bands was measured using
ImageQuant software version 7.0 (GE Healthcare) and normalized to that of
β-actin. (Right) The fold change (p19ARF/β-actin) is shown. (E and F) Quan-
titative PCR analysis of ARF mRNA levels (E) or analysis of ARF promoter
activity (F) in the MTA1+/+ and MTA1−/− MEFs (Left) or the HC11/pcDNA and
HC11/MTA1 cells (Right). (G) p53−/−/Mmd2−/− cells were transfected with the
ARF-luciferase reporter plasmid (p19ARF-Luc) alone or in combination with
increasing amounts of a Myc-MTA1 expression plasmid. ARF-luciferase ac-
tivity was determined as described in SI Appendix, SI Materials and Methods.
*P < 0.05; **P < 0.01.
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stimulates ARF gene transcription by recruiting the c-Jun/MTA1/
Pol II complex onto the ARF promoter.
ARF Negatively Regulates MTA1 Expression Independent of p53 and
c-Myc. Because of the putative growth-inhibitory activity of ARF
(11), we next determined the potential feedback effect of ARF
on the MTA1 pathway. Interestingly, we observed a marked
accumulation of MTA1, but not MTA2, protein in p19ARF−/−
MEFs compared with wild-type controls (Fig. 3A). In contrast,
induced expression of p19ARF inhibited the protein expression
of MTA1 in p53−/−/Mdm2−/− MEFs (Fig. 3B), indicating that the
inhibitory effect of ARF on MTA1 expression is independent of
the Mdm2/p53 pathway. Because ARF negatively regulates the
expression of c-Myc oncoprotein (19), and MTA1 is the down-
stream effector of c-Myc (6), we next examined whether negative
regulation of MTA1 by ARF is mediated by c-Myc. Results
showed that induced expression of ARF resulted in markedly
reduced levels of endogenous MTA1 protein in both c-Myc+/+
and c-Myc−/− MEFs (20), indicating that the observed effect of
ARF on MTA1 expression is also independent of c-Myc (Fig.
3C). We also observed that induced expression of ARF in c-
Myc+/+ MEFs resulted in a significant down-regulation of c-Myc
expression (compare lane 2 and lane 1), and the protein levels of
MTA1 in c-Myc−/− MEFs were reduced relative to c-Myc+/+
controls (compare lane 3 and lane 1). These results enabled us to
identify ARF as a bona fide negative regulator of MTA1 in-
dependent of p53 and c-Myc.
ARF Inhibits MTA1 Transcription. While investigating whether ARF
affects the transcription of MTA1, we found that knockout of
ARF resulted in a significant increase in the levels of MTA1
mRNA compared with wild-type controls (Fig. 3D Left). In con-
trast, induced expression of ARF in p53−/−/Mdm2−/− cells resulted
in a significant decrease in MTA1 mRNA levels (Fig. 3D Right).
To validate the significance of these findings, we next analyzed the
transcription levels of MTA1 and ARF in a published cDNA
microarray database by Miller et al. (21) in which the global
transcript profiles of 251 p53-sequenced primary breast tumors
were analyzed usingAffymetrixU133 oligonucleotidemicroarrays.
We found an inverse correlation in the transcription levels of ARF
andMTA1 genes in these breast tumors independent of p53 status
(SI Appendix, Fig. S10). Furthermore, induced expression of ARF
in p53−/−/Mdm2−/− cells inhibited MTA1 promoter activity in a
dose-dependent manner (Fig. 3E). Together, these results clearly
suggest that ARF inhibits MTA1 expression, at least in part, at the
transcriptional level independently of p53 and c-Myc.
ARF and SP1 Are Corecruited onto the MTA1 Promoter. To un-
derstand themechanism by which ARF inhibitsMTA1 expression,
we next used a ChIP-based promoter walk analysis to test whether
ARF binds to the MTA1 promoter and found that p19ARF was
recruited to only one (R1) of the four regions of the MTA1 pro-
Fig. 2. Recruitment of the c-Jun/MTA1/Pol II coactivator com-
plex onto the ARF promoter. (A) Line diagram showing the
regions of p19ARF promoter analyzed. (B and C) ChIP analysis
for the recruitment of MTA1 onto the ARF promoter in the
MTA1+/+ andMTA1−/− MEFs (B) or HC11/pcDNA and HC11/MTA1
cells (C). (D) Double ChIP analysis for the recruitment of the
MTA1/Pol II complex onto the ARF promoter using HC11/pcDNA
and HC11/MTA1 cells. The first ChIP with an anti-MTA1 antibody
was followed by a second ChIP with an anti-Pol II antibody. (E)
Double ChIP analysis for the recruitment of the MTA1/c-Jun
complex onto the ARF promoter using HC11/pcDNA and HC11/
MTA1 cells. The first ChIP with an anti-MTA1 antibody was fol-
lowed by a second ChIP with an anti–c-Jun antibody. (F) EMSA
analysis of MTA1/c-Jun protein complex binding to the ARF
promoter using a PCR product encompassing the MTA1 and c-
Jun consensus sequence in the MTA1+/+ and MTA1−/− MEFs. Ab,
antibody; PC, pcDNA.
Fig. 3. ARF inhibits MTA1 expression independently of p53 and c-Myc. (A)
Western blot analysis of the ARF+/+ and ARF−/− MEFs with the indicated anti-
bodies. (B and C) p53−/−/Mdm2−/− (B) and c-Myc+/+ and c-Myc−/−MEFs (C) were
transfected with the indicated expression vectors and subjected to Western
blot analysis with the indicated antibodies. (D) Quantitative PCR analysis of
MTA1 mRNA levels in ARF+/+ and ARF−/− MEFs (Left) and in p53−/−/Mdm2−/−
MEFs transfected with an ARF expression plasmid or empty vector control
plasmid (Right). (E) p53−/−/Mdm2−/− cells were transfected with a pGL3-MTA1–
luciferase reporter plasmid alone or in combination with increasing amounts
of an ARF expression plasmid, andMTA1-luciferase activity was determined as
described above. *P < 0.05; **P < 0.01.











moter in the p19ARF+/+ but not p19ARF−/− (negative control)
MEFs (Fig. 4 A and B and SI Appendix, Fig. S11). Sequence
analysis of this region using the Alibaba 2.1 program revealed the
presence of seven putative consensus binding sequences for the
transcription factor specificity protein 1 (SP1) (SI Appendix, Fig.
S12), indicating a possible contribution of SP1 to the transcrip-
tional regulation of MTA1. ChIP analysis using an anti-SP1 anti-
body revealed that SP1 is recruited to three distinct regions (R1,
R2, andR4) of theMTA1 promoter inMTA1+/+ but notMTA1−/−
MEFs (Fig. 4C and SI Appendix, Fig. S13). We next determined
whether SP1 protein binds to the MTA1 promoter DNA using
EMSA analysis of the nuclear extracts from ARF−/− MEFs. As
shown inFig. 4D, we found a distinct protein/MTA1DNAcomplex
that could be supershifted by incubation of the nuclear extracts
with a specific antibody against SP1 (lane 3) but not ARF (negative
control) (lane 4) or control IgG (lane 5) at the expense of basal
protein/MTA1 DNA complexes (lane 2), confirming that SP1
protein interacts specifically with MTA1 promoter DNA. In sup-
port of these findings, induced expression of SP1 dramatically
stimulated MTA1 transcription in a dose-dependent manner (SI
Appendix, Fig. S14A, lanes 3–5). In contrast, treatment of cells with
mithramycin A (MMA), an aureolic acid antibiotic that has been
shown to inhibit SP1-mediated transcriptional activation selec-
tively (22), resulted in a significant reduction in SP1-mediated
transactivation ofMTA1 promoter activity (SIAppendix, Fig. S14A,
lanes 6–8). Consistently, MMA-based treatment remarkably de-
creased themRNA levels ofMTA1 in a dose- and time-dependent
manner (SI Appendix, Fig. S14B). These results suggest that SP1 is
recruited onto the MTA1 promoter and stimulates MTA1
gene transcription.
To determine whether the ARF/SP1 complex associates with
the murine MTA1 promoter, we next performed a sequential
double-ChIP analysis using the indicated antibodies and found
that SP1 and ARF are corecruited only onto the ARF-MTA1
promoter–interacting region R1 (Fig. 4E and SI Appendix, Fig.
S15). To validate these findings further in human cells, we next
carried out ChIP analyses using an anti-p14ARF antibody in the
H1299 cells and found the recruitment of p14ARF onto two
regions of the humanMTA1 promoter (R4 and R6) (SI Appendix,
Fig. S16 A and B). A double ChIP analysis revealed the re-
cruitment of both SP1 and p14ARF to only one region (R6) (SI
Appendix, Fig. S16C). Sequence analysis using the Alibaba 2.1
program revealed the conservation of SP1 consensus binding
sequences in this region (SI Appendix, Fig. S16D).
We next determined whether ARF/SP1 complex binds toMTA1
promoter DNA using EMSA analysis. As shown in Fig. 4F, we
found a distinct protein/MTA1 DNA complex that could be
supershifted by incubation of the nuclear extracts fromp19ARF+/+
MEFs with a specific antibody against SP1 (lane 3) or ARF (lane 4)
but not control IgG (lane 6) at the expense of basal protein/MTA1
DNA complexes (lane 2), suggesting that both ARF and SP1
proteins may interact with the MTA1 promoter. This notion is
supported by the finding that coincubation of anti-SP1 and anti-
ARF antibodies resulted in the formation of further higher-
molecular-weight protein/DNA complexes (lane 5).
ARF Promotes SP1 Proteasomal Degradation by Enhancing Its
Interaction with Proteasome Subunit Regulatory Particle ATPase 6.
Our findings that SP1 and ARF are corecruited onto the MTA1
promoter raised the possibility of physical interaction between
ARF and SP1 proteins. To test this notion, HEK293T cells were
transfected with expression vectors encoding Flag-tagged SP1 and
Myc-tagged ARF, and protein extracts were subjected to the se-
quential immunoprecipitation/Western blot analysis with the in-
dicated antibodies. Results showed that exogenously expressed
Flag-SP1 but not control IgG could be coimmunoprecipitated ef-
fectively withMyc-ARF, suggesting that the two proteins interact in
vivo (Fig. 5A andB). Furthermore, therewas an interaction between
SP1 and ARF at the endogenous protein level in p53−/−/Mdm2−/−
cells (Fig. 5C). Confocal scanning microscopy data also demon-
strated that SP1 colocalizes with ARF in ARF+/+ but not ARF−/−
MEFs (Fig. 5D). To determine whether the interaction between
ARF andSP1 is direct and to characterize their interacting domains,
we performed GST pull-down assays. Results showed that ARF
protein binds efficiently to the B (lane 5) and DBD domains of SP1
(lane 8) (SI Appendix, Fig. S17A), whereas SP1 binds to the N-ter-
minal region of ARF protein (SI Appendix, Fig. S17B).
We next examined the possibility that ARF promotes degrada-
tion of SP1, thereby abrogating its coactivator activity uponMTA1
transcription. Indeed, we found that the protein levels of SP1 were
increased significantly in ARF−/− MEFs compared with wild-type
controls (Fig. 5E). Furthermore, induced expression of ARF in
p53−/−/Mdm2−/− cells distinctly reduced the endogenous SP1
protein expression in a dose-dependent manner (Fig. 5F). Inter-
estingly, the ARF-mediated degradation of SP1 was blocked ef-
fectively by treating cells with the proteasome inhibitor MG132
(Fig. 5G), suggesting that down-regulation of SP1 by ARF was
occurring, at least in part, through the proteasome (although we
could not rule out the possibility of other alternative mechanisms
in the noted down-regulation of SP1 by ARF).
In line with these findings, we next observed that ARF distinctly
potentiated the levels of SP1 ubiquitination and that this modifi-
cation was accompanied by SP1 down-regulation (SI Appendix,
Fig. S18A). Previous studies revealed that a subunit of the 26S
proteasome, regulatory particle ATPase 6 (Rpt6), could interact
with SP1 (23), and the interaction increases the efficiency of SP1
proteolytic processing and ubiquitination and then results in SP1
degradation (24). We next examined whether ARF augments the
interaction of SP1 with Rpt6, resulting in increased proteasome
degradation of SP1. As shown in SI Appendix, Fig. S18B, knockout
of ARF decreased the interaction of SP1 with Rpt6 (compare lane
3 and lane 2) at endogenous levels. In contrast, increased accu-
mulation of SP1 protein was shown clearly in ARF−/− cells com-
pared with wild-type controls (compare lane 6 and lane 5). Thus,
we concluded that ARF interacts with SP1 and promotes its pro-
teasomal degradation by enhancing its interaction with protea-
some subunit Rpt6, thereby abrogating the ability of SP1 to
stimulate MTA1 transcription. However, because the SP1-ARF
complex is recruited to theMTA1 promoter, we could not rule out
the possibility that ARF localized to theMTA1 promoter prevents
Fig. 4. ARF and SP1 are corecruited onto the MTA1 promoter. (A) Line di-
agram showing the regions of the mMTA1 promoter analyzed. (B and C)
ChIP analysis for the recruitment of ARF (B) or SP1 (C) onto the MTA1 pro-
moter as described above. (D) EMSA analysis of SP1 protein binding to the
MTA1 promoter DNA. (E) Double ChIP analysis for the recruitment of the
SP1/ARF complex onto the MTA1 promoter using MTA1+/+ and MTA1−/−
MEFs (negative controls). The first ChIP with an anti-SP1 antibody was fol-
lowed by a second ChIP with an anti-p19ARF antibody. (F) EMSA analysis of
SP1/ARF protein complex binding to the MTA1 promoter DNA using nuclear
extracts from p19ARF+/+ MEFs.
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SP1-mediated transcription. We further demonstrated that more
SP1 protein was recruited onto the MTA1 promoter in ARF−/−
MEFs than in ARF+/+ controls (SI Appendix, Fig. S19) and that
exogenous ARF inhibited both basal and SP1-mediated stimula-
tion of MTA1 promoter activity (SI Appendix, Fig. S20).
ARF Affects the Protein Stability of MTA1. Previous studies have
demonstrated that ARF affects protein stability of its binding
partners by inducing 26S proteasome-mediated degradation (11).
Recently, MTA1 protein has been shown to be targeted for deg-
radation by a ubiquitin–proteasome pathway (25). Therefore, we
next testedwhether ARF also affects the protein stability ofMTA1
in addition to its characterized role inMTA1 transcription. To this
aim, we first tested whether ARF interacts with MTA1 in p53−/−/
Mdm2−/− cells transfected with an expression vector encoding
Myc-tagged MTA1 (Myc-MTA1) alone or in combination with
Flag-tagged ARF (Flag-ARF). As shown in SI Appendix, Fig.
S21A, Myc-MTA1 and Flag-ARF are coimmunoprecipitated only
when coexpressed (lane 2), indicating that these two proteins can
interact in vivo and that the interaction of both proteins is specific
because Flag-ARF is not immunoprecipitated whenMyc-MTA1 is
expressed alone (lane 1).More importantly, usingMTA1−/−MEFs
(13) as negative controls, we found an interaction between the
endogenous MTA1 and ARF in MTA1+/+ but not in MTA1−/−
MEFs (SI Appendix, Fig. S21B), suggesting that ARF and MTA1
proteins can form a stable complex in physiologically relevant
settings. It also was noticed that induced expression of ARF
protein in p53−/−/Mdm2−/− cells resulted in a significant down-
regulation of exogenously expressed Myc-MTA1 (SI Appendix,
Fig. S21A). These results indicate that ARF also could affect the
MTA1protein function, in addition to its role inMTA1 transcription.
In support of this notion, we found that ARF-mediated degradation
of MTA1 in H1299 cells was partially blocked by treating the cells
with the proteasome inhibitor MG132 (SI Appendix, Fig. S21C),
suggesting that the ubiquitin–proteasome pathway also is involved in
the regulation of MTA1 by ARF. Further, we observed that ARF
distinctly potentiates the levels of MTA1 ubiquitination, and this
modification is accompanied by MTA1 down-regulation (SI Ap-
pendix, Fig. S21D). Together, these results strongly support the no-
tion that ARFmight affect the protein stability ofMTA1 in addition
to affecting MTA1 transcription.
ARF Inhibits MTA1-Mediated Transactivation Activity and Cell
Migration and Invasion. We next sought to determine whether
ARF influences the biologic functions of MTA1. To this end, we
first tested the effect of ARF on the activity of MTA1-responsive
promoters. We found that induced expression of MTA1 alone
increases BCAS3 andNF-κB promoter activity in theHC11 cells, as
reported previously (4, 26). However, coexpression of ARF coun-
teracted the ability of MTA1 to transactivate the BCAS3 (SI Ap-
pendix, Fig. S22A) and NF-κB promoters (SI Appendix, Fig. S22B).
Fig. 5. ARF associates with SP1 and promotes its proteasome
degradation. (A and B) HEK293T cells were transfected with
expression vectors encoding Myc-ARF and Flag-SP1. Protein
extracts were immunoprecipitated with control IgG or an anti-
Flag antibody (A) or with anti-Myc antibody (B) and were
immunoblotted with the indicated antibodies. (C) Protein
extracts from p53−/−/Mdm2−/− cells were subjected to immu-
noprecipitation analysis with an anti-p19ARF antibody or
control IgG, followed by Western blotting using the indicated
antibodies. (D) ARF+/+ or ARF−/− MEFs were incubated with
anti-SP1 and anti-p19ARF antibodies and then were labeled
with Alexa Fluor 488- and Texas Red-conjugated secondary
antibodies and analyzed by confocal microscopy. (E) Western
blot analysis of the protein expression of SP1 and ARF in the
ARF+/+ and ARF−/− MEFs. (F) p53−/−/Mdm2−/− cells were trans-
fected with or without increasing amounts of a Flag-ARF ex-
pression plasmid and subjected to immunoblotting with the
indicated antibodies. (G) p53−/−/Mdm2−/− cells were trans-
fected with a Flag-ARF expression vector or empty vector
control plasmid. After 48 h of transfection, cells were treated
with DMSO or 20 μM of MG132 for 6 h and then were
immunoblotted with the indicated antibodies.
Fig. 6. An integrated working model. ARF is induced by MTA1-mediated
oncogenic signals through the corecruitment of c-Jun onto the ARF pro-
moter. ARF, in turn, inhibits MTA1 expression by blocking the SP1-mediated
transactivation of MTA1 or affecting its protein stability. This inhibition
creates a bidirectional autoregulatory feedback loop that acts in concert to
regulate cell homeostasis and oncogenesis, depending on the cellular con-
text and the environment.











MTA1 has been identified as one of the critical players in cancer
cell migration and invasion (27), and emerging evidence has shown
that ARF negatively regulates cell migration and invasion by tar-
geting different signaling pathways (28). In light of these findings,
we next determined whether ARF counteracts the MTA1-
mediated migratory and invasive potential of cancer cells. Boyden
chamber assay revealed that coexpression of ARF attenuates
MTA1-mediated cell migration and invasion (SI Appendix, Fig.
S22C). These results suggest that the observed bidirectional reg-
ulatory relationship between ARF and MTA1 has functional im-
plications in counteracting the oncogenic activity of MTA1.
To characterize further the significance of these findings, we
analyzed the correlation of ARF-high/MTA1-low and ARF-low/
MTA1-high transcriptional levels with disease-specific survival in
251 primary breast tumors (21). When wild-type p53 was present,
the patterns of the MTA1/ARF transcriptional levels had no sig-
nificant effect on disease-specific survival of these patients with
primary breast tumors (SI Appendix, Fig. S23 A and B). In-
terestingly, ARF-low/MTA1-high transcriptional levels correlated
well with reduced disease-specific survival in breast cancer patients
harboring mutant p53 (SI Appendix, Fig. S23C). Although it is not
surprising that the disease-specific survival in human breast cancer
patients was reduced with the lack of the tumor suppressors p53
and ARF (SI Appendix, Fig. S23C, red line), the distinct effect of
ARF-high/MTA1-low transcriptional levels on the disease-specific
survival is evidently shown (SI Appendix, Fig. S23C, green line)
in the absence of p53, emphasizing the possible major p53-
independent role of ARF. These findings further highlight the
primary importance of p53 functional status in predicting the be-
havior of breast cancer (23). As a result, the functional role of the
MTA1–ARF loop may be overlapped in breast tumors expressing
wild-type p53. In the absence of functional p53, however, the
MTA1–ARF regulatory loop would exert its dominant role in
breast cancer prognosis.
In summary, the findings presented here establish that the ARF
gene is induced by MTA1-mediated oncogenic signals through the
corecruitment of c-Jun onto the ARF promoter. ARF, in turn,
inhibits MTA1 expression by blocking transcription factor SP1-
mediated transactivation or by affecting its protein stability, thus
creating an autoregulatory feedback loop that regulates both
MTA1 and ARF activities in a p53-independent manner (Fig. 6).
Given the evidence that MTA1 transactivates ARF and ARF
counteracts MTA1, the interplay between the ARF tumor sup-
pressor and the MTA1 oncogene is likely to maintain a delicate
control of cell homeostasis in normal cells. When the amount of
MTA1 exceeds normal cellular proliferation levels, a safeguard
mechanism needs to be activated whereby MTA1 induces ARF,
which in turn down-regulatesMTA1 (Fig. 6Upper). As is often the
case with p53, the ARF/INK4A locus is inactivated by complete
deletion or mutation or aberrant promoter methylation in about
30% of all known types of malignancies (29). Thus, the loss of
ARF in cancer cells could contribute to MTA1-induced tumori-
genesis by at least two mechanisms. The down-regulation of ARF
results in unrestricted MTA1-mediated cell proliferation and
transformation resulting from the absence of an “oncogenic
checkpoint.” Another important consequence of ARF suppres-
sion or loss might result in increased MTA1 levels and signaling
through a negative feedback mechanism, further fueling the on-
cogenic activity of MTA1 (Fig. 6 Lower). Therefore, bidirectional
ARF–MTA1 signaling represents an important fail-safe mecha-
nism for preventing MTA1-mediated tumorigenesis and tumor
progression through the control of MTA1 activities. Certainly,
further investigations of the ARF–MTA1 axis in mouse and hu-
man cancer are likely to yield important insights into mechanisms
of tumor progression, providing leads for the therapeutic targeting
of this pathway in cancer biology.
Materials and Methods
HEK293T and H1299 cells were obtained from ATCC. p53−/−/Mdm2−/−,
p19ARF−/−, and c-Myc−/− MEFs and their corresponding wild-type counter-
parts were kindly provided by Guillermina Lozano (M.D. Anderson Cancer
Center, Houston, TX), Yanping Zhang (University of North Carolina at Chapel
Hill, Chapel Hill, NC), and Ignacio Moreno de Alborán (National Center for
Biotechnology, Madrid, Spain), respectively. MTA1+/+ and MTA1−/− MEFs
were generated in our laboratory from embryos at day 9 of development
(13). All cell lines were grown in media recommended by the providers
supplemented with 10% FBS and 1× antibiotic-antimycotic solution in a hu-
midified 5% CO2 atmosphere at 37 °C. Materials and methods used are
discussed in detail in SI Appendix, SI Materials and Methods. Primers used for
ChIP assay are provided in SI Appendix, Tables S2–S5, and primers used for
quantitative PCR analysis are given in SI Appendix, Table S6.
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